CAI Stock Analysis: Buy, Sell, or Hold?
CAI - Caris Life Sciences, Inc. Common Stock
$15.67
-0.42 (-2.61%)
▼
5d:
+0.97%
30d:
-16.43%
90d:
-17.53%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
2d
Get Alerted When CAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CAI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CAI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.32
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.75
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CAI is currently trading at $15.67, which is considered oversold relative to its 30-day fair value range of $15.85 to $18.06. The stock's valuation (Forward PE: 44.0) is in line with its historical norms (48.2). Remarkably, the market is currently pricing in an annual earnings decline of 3.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CAI is in a downtrend. Immediate support is located at $15.11, while resistance sits at $16.49.
Market Sentiment: CAI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $27.00 (+72.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CAI is in a downtrend. Immediate support is located at $15.11, while resistance sits at $16.49.
Market Sentiment: CAI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $27.00 (+72.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$15.85 -
$18.06
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 72.3% below Wall St target ($27.00)
Trading Range Analysis
30-Day Trading Range
$15.85 -
$18.06
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$15.11
Resistance Level
$16.49
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
44.05
Wall Street Target
$27.00
(+72.3%)
Revenue Growth (YoY)
78.8%
Profit Margin
3.8%
Valuation Discount vs History
-3.0% cheaper
PE vs Historical
44.1 vs 48.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.0%
(market-implied from PE analysis)
1-Year Target
$15.20
(-3%)
2-Year Target
$14.74
(-6%)
3-Year Target
$14.30
(-9%)
3-Yr Target (if PE normalizes)
(PE: 44→48)
$15.65
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 44.1, Growth: 173.8%)
$52.89
(+238%)
Base:
(SPY PE: 20.7, Growth: 173.8%)
$24.89
(+59%)
Bear:
(PE: 17.6, Growth: 173.8%)
$21.15
(+35%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 44.1 to 48.2
Stabilization Target:
$17.14
(+9.4%)
PE Expansion Potential:
+9.4%
Share & Embed Analysis
Last updated: August 02, 2026 11:03 AM ET
Data refreshes hourly during market hours. Next update: 12:03 PM
Data refreshes hourly during market hours. Next update: 12:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |